Last reviewed · How we verify
Dimazon (diacetazotol)
Dimazon (generic name: diacetazotol) is a drug. It is currently in unknown development.
Dimazon works by binding to a specific target, although its exact mechanism of action is currently unknown.
Dimazon (diacetazotol) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, and bioavailability. Further research is needed to understand its mechanism of action and key safety considerations. As a result, Dimazon is not widely recognized in the pharmaceutical industry.
At a glance
| Generic name | diacetazotol |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine Dimazon as a key that fits into a lock on a cell. When it binds to its target, it can either turn the lock on or off, depending on the cell's needs. This can help to regulate various cellular processes and treat certain diseases.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimazon CI brief — competitive landscape report
- Dimazon updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Dimazon
What is Dimazon?
How does Dimazon work?
What is the generic name of Dimazon?
What development phase is Dimazon in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing